Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT06146777 trial: what clinicians have said so far
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
- NCT06146777 ↗
- Not yet recruiting
- First Affiliated Hospital, Sun Yat-Sen University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT06146777 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06146777 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System
- Phase
- Phase 3
- Status
- Not yet recruiting
- Conditions
- Papillary Renal Cell Carcinoma
- Interventions
- Pembrolizumab; Placebo
- Arms
- Pembrolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 468 (estimated)
- Primary outcomes
- Disease-free survival
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Start
- Dec 1, 2023 (estimated)
- Primary completion
- Dec 1, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06146777 · updated Nov 29, 2023